Fol. Biol. 2016, 62, 258-262

https://doi.org/10.14712/fb2016062060258

Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma

Jan H. Živný1, S. Leahomschi2, P. Klener, Jr.1,3, J. Živný2, M. Haluzík4, D. Cibula2

1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Czech Republic
2Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
31st Department of Medicine – Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
4Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic

Received May 2016
Accepted June 2016

References

1. Bagade, P., Edmondson, R., Nayar, A. (2012) Management of borderline ovarian tumours. The Obstetrician & Gynaecologist 14, 115-120. <https://doi.org/10.1111/j.1744-4667.2012.00102.x>
2. Bao, L. H., Sakaguchi, H., Fujimoto, J., Tamaya, T. (2007) Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J. Biomed. Sci. 14, 373-81. <https://doi.org/10.1007/s11373-006-9143-1>
3. Brakora, K. A., Lee, H., Yusuf, R., Sullivan, L., Harris, A., Colella, T., Seiden, M. V. (2004) Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol. Oncol. 93, 361-365. <https://doi.org/10.1016/j.ygyno.2004.01.050>
4. Chakraborty, G., Jain, S., Behera, R., Ahmed, M., Sharma, P., Kumar, V., Kundu, G. C. (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. 6, 819-830. <https://doi.org/10.2174/156652406779010803>
5. Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A. F., Yeatman, T. J. (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 10, 184-190. <https://doi.org/10.1158/1078-0432.CCR-1405-2>
6. Díaz-Padilla, I., Razak, A. R., Minig, L., Bernardini, M. Q., María Del Campo, J. (2012) Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls. Clin. Transl. Oncol. 14, 15-20. <https://doi.org/10.1007/s12094-012-0756-8>
7. El-Tanani, M. K., Campbell, F. C., Kurisetty, V., Jin, D., McCann, M., Rudland, P. (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 17, 463-474. <https://doi.org/10.1016/j.cytogfr.2006.09.010>
8. Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., Fisher, L. W. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 7, 4060-4066.
9. Fischerova, D., Zikan, M., Dundr, P., Cibula, D. (2012) Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist 17, 1515-1533. <https://doi.org/10.1634/theoncologist.2012-0139>
10. Hu, Z. D., Wei, T. T., Yang, M., Ma, N., Tang, Q. Q., Qin, B. D., Fu, H. T., Zhong, R. Q. (2015) Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One 10, e0126444. <https://doi.org/10.1371/journal.pone.0126444>
11. Jelovac, D., Armstrong, D. K. (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin, 61, 183-203. <https://doi.org/10.3322/caac.20113>
12. Kim, J. H., Skates, S. J., Uede, T., Wong, K. K., Schorge, J. O., Feltmate, C. M., Berkowitz, R. S., Cramer, D. W., Mok, S. C. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J. Am. Med. Assoc. 287, 1671-1679. <https://doi.org/10.1001/jama.287.13.1671>
13. Kothari, A. N., Arffa, M. L., Chang, V., Blackwell, R. H., Syn, W. K., Zhang, J., Mi, Z., Kuo, P. C. (2016) Osteopontin – a master regulator of epithelial-mesenchymal transition. J. Clin. Med. 5, pii: E39. <https://doi.org/10.3390/jcm5040039>
14. Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., Giachelli, C. M. (1995) The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of αvβ3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest. 95, 713-724. <https://doi.org/10.1172/JCI117718>
15. Medeiros, L. R., Rosa, D. D., da Rosa, M. I., Bozzetti, M. C. (2009) Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 142, 99-105. <https://doi.org/10.1016/j.ejogrb.2008.08.011>
16. Milivojevic, M., Boskovic, V., Atanackovic, J., Milicevic, S., Razic, S., Kotlica, B. K. (2013) Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma. Eur. J. Gynaecol. Oncol. 34, 83-85.
17. Mor, G., Visintin, I., Lai, Y., Zhao, H., Schwartz, P., Rutherford, T., Yue, L., Bray-Ward, P., Ward, D. C. (2005) Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 102, 7677-7682. <https://doi.org/10.1073/pnas.0502178102>
18. Moszynski, R., Szubert, S., Szpurek, D., Michalak, S., Sajdak, S. (2013) Role of osteopontin in differential diagnosis of ovarian tumors. J. Obstet. Gynaecol. Res. 39, 1518-1525. <https://doi.org/10.1111/jog.12097>
19. Nakae, M. 1., Iwamoto, I., Fujino, T., Maehata, Y., Togami, S., Yoshinaga, M., Douchi, T. (2006) Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32, 309-314. <https://doi.org/10.1111/j.1447-0756.2006.00403.x>
20. Prat, J., FIGO Committee on Gynecologic Oncology. FIGO Guidelines. (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 124, 1-5. <https://doi.org/10.1016/j.ijgo.2013.10.001>
21. Rittling, S. R., Chambers, A. F. (2004) Role of osteopontin in tumour progression. Br. J. Cancer 90, 1877-1881. <https://doi.org/10.1038/sj.bjc.6601839>
22. Rosenthal, A. N., Menon, U., Jacobs, I. J. (2006) Screening for ovarian cancer. Clin. Obstet. Gynecol. 49, 433-447. <https://doi.org/10.1097/00003081-200609000-00004>
23. Schorge, J. O., Drake, R. D., Lee, H., Skates, S. J., Rajanbabu, R., Miller, D. S., Kim, J. H., Cramer, D. W., Berkowitz, R. S., Mok, S. C. (2004) Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin. Cancer. Res. 10, 3474-3478. <https://doi.org/10.1158/1078-0432.CCR-03-0365>
24. Sodek, J., Ganss, B., McKee, M. D. (2000) Osteopontin. Crit. Rev. Oral Biol. Med. 11, 279-303. <https://doi.org/10.1177/10454411000110030101>
25. Sokalska, A., Timmerman, D., Testa, A. C., Van Holsbeke, C., Lissoni, A. A., Leone, F. P., Jurkovic, D., Valentin, L. (2009) Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound Obstet. Gynecol. 34, 462-470. <https://doi.org/10.1002/uog.6444>
26. Song, G., Cai, Q. F., Mao, Y. B., Ming, Y. L., Bao, S. D., Ouyang, G. L. (2008) Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1α expression through the PI3-K/Akt pathway. Cancer Sci. 99, 1901-1907. <https://doi.org/10.1111/j.1349-7006.2008.00911.x>
27. Standal, T., Hjorth-Hansen, H., Rasmussen, T., Dahl, I. M., Lenhoff, S., Brenne, A. T., Seidel, C., Baykov, V., Waage, A., Borset, M., Sundan, A., Hjertner, O. (2004) Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 89, 174-182.
28. Trillsch, F., Mahner, S., Ruetzel, J., Harter, P., Ewald-Riegler, N., Jaenicke, F., du Bois, A. (2010) Clinical management of borderline ovarian tumors. Expert Rev. Anticancer Ther. 10, 1115-1124. <https://doi.org/10.1586/era.10.90>
29. Uzan, C., Kane, A., Rey, A., Gouy, S., Duvillard, P., Morice, P. (2010) Outcomes after conservative treatment of advanced- stage serous borderline tumors of the ovary. Ann. Oncol. 21, 55-60. <https://doi.org/10.1093/annonc/mdp267>
30. Wai, P. Y., Kuo, P. C. (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 27, 103-118. <https://doi.org/10.1007/s10555-007-9104-9>
31. Zanetta, G., Rota, S., Chiari, S., Bonazzi, C., Bratina, G., Mangioni, C. (2001) Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J. Clin. Oncol. 19, 2658-2664. <https://doi.org/10.1200/JCO.2001.19.10.2658>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive